	US 12,186,377 B2
	Modulation of oxidative stress and amino acid metabolism for the treatment or prevention of diseases and disorders
Thales Papagiannakopoulos, Brooklyn, NY (US)
Assigned to New York University, New York, NY (US)
Filed by NEW YORK UNIVERSITY, New York, NY (US)
Filed on Sep. 23, 2020, as Appl. No. 17/029,237.
Claims priority of provisional application 62/904,256, filed on Sep. 23, 2019.
Prior Publication US 2021/0085763 A1, Mar. 25, 2021
Int. Cl. A61K 38/00 (2006.01); A61K 31/4164 (2006.01); A61K 31/554 (2006.01); A61K 33/26 (2006.01); A61K 38/44 (2006.01); A61K 38/50 (2006.01); A61K 38/51 (2006.01); A61P 35/00 (2006.01)

CPC A61K 38/51 (2013.01) [A61K 31/4164 (2013.01); A61K 31/554 (2013.01); A61K 33/26 (2013.01); A61K 38/443 (2013.01); A61K 38/50 (2013.01); A61P 35/00 (2018.01)]

2 Claims

1. A method for treating or preventing tumor growth or metastasis in a subject in need thereof, the method comprising:

a) detecting at least one selected from the group consisting of a decreased level of Keap1 activity, and an inactivating mutation of Keap1, in the tumor; and

b) administering to the subject a composition, or treatment regimen, selected from the group consisting of:

i) an agent or treatment regimen for reducing the level of at least one amino acid comprising at least one selected from the group consisting of an asparaginase, a serine degrading enzyme, an inhibitor of phosphoserine aminotransferase, an inhibitor of an amino acid transporter, wherein the amino acid is selected from the group consisting of glutamate, glutamine, proline, serine, alanine, glycine, arginine, lysine, asparagine, methionine, threonine, and isoleucine, an inhibitor of glutaminase (GLS), an inhibitor of glutamate dehydrogenase (GLUD), an aminotransferase inhibitor, and a competitive inhibitor of glutamine;

ii) an agent for inhibiting the pentose phosphate pathway (PPP) comprising an inhibitor of at least one selected from the group consisting of glucose-6-phosphate dehydrogenase (G6PD or G6PDH), 6-phosphogluconolactonase, 6-phosphogluconate dehydrogenase, fructose-bisphosphate aldolase B, ribose-5-phosphate isomerase, Ribulose 5-Phosphate 3-Epimerase, transaldolase, solute carrier family 16 member 1 (SLC16A1 or MCT1) and lactate dehydrogenase A (LDHA);

iii) an agent for inhibiting the sorbitol pathway comprising an inhibitor of at least one selected from the group consisting of sorbitol dehydrogenase (SORD), ketohexokinase, Triokinase and FMN Cyclase (TKFC), aldo-keto reductase family 1, member B1 (AKR1b1), aldo-keto reductase family 1, member B3 (AKR1b3), aldo-keto reductase family 1, member B7 (AKR1b7), aldo-keto reductase family 1, member B8 (AKR1b8), aldo-keto reductase family 1, member B10 (AKR1b10), sterol regulatory element binding protein-1c (SREBP-1c), Carbohydrate-responsive element-binding protein (ChREBP), fructose transporter solute carrier family 2 member 5 (SLC2A5 or GLUT5), solute carrier family 16 member 1 (SLC16A1 or MCT1) or lactate dehydrogenase A (LDHA); and

iv) an agent for inhibiting the heme biosynthesis pathway comprising an inhibitor of at least one selected from the group consisting of 5-aminolevulinic acid synthase-1 (ALAS1), delta-aminolevulinic acid dehydratase (ALAD), hydroxymethylbilane synthase (HMBS), uroporphyrinogen III synthase (UROS), uroporphyrinogen decarboxylase (UROD), coproporphyrinogen oxidase (CPOX), protoporphyrinogen oxidase (PPOX), transmembrane protein 14C (TMEM14C), FLVCR heme transporter 1 (FLVCR1), solute carrier family 48 member 1 (SLC48A1) or ferrochelatase (FECH).